(Q34194396)

31 July 2017

1 reference

title

Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers (English)

1 reference

31 July 2017

0 references

0 references

Bolte AC

1

1 reference

31 July 2017

van Geijn HP

series ordinal

2

1 reference

31 July 2017

Dekker GA

series ordinal

3

1 reference

31 July 2017

publication date

1 March 2001

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

31 July 2017

published in

1 reference

31 July 2017

volume

95

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

22-36

1 reference

Management of pre-eclampsia

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Confidential enquiry into maternal deaths in The Netherlands 1983-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The pharmacological management of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Drug management of hypertensive disorders of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Treatment of hypertension in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Maternal central hemodynamics in hypertensive disorders of pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Haemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Respiratory function in severe gestational proteinuric hypertension: the effects of rapid volume expansion and subsequent vasodilatation with verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Cardiovascular alterations in severe pregnancy-induced hypertension: effects of intravenous nitroglycerin coupled with blood volume expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe pre-eclampsia remote from term

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

How Should Hypertension During Pregnancy Be Managed?: Experience at Parkland Memorial Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The response of plasma catecholamines to intravenous labetalol: a comparison with sodium nitroprusside

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Oral nifedipine therapy in the management of severe preeclampsia.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Single dose of labetalol in normotensive pregnancy: effects on maternal hemodynamics and uterine and fetal flow velocity waveforms

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Half-life of maternal labetalol in a premature infant

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Severe adverse effects of maternal labetalol in a premature infant

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Neonatal adrenergic blockade following single dose maternal labetalol administration

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Minibolus diazoxide in the management of severe hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Infusion of diazoxide in severe hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Magnesium: Nature's physiologic calcium blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Nifedipine and beta-blockade as a cause of cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Prevention of eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The use of nimodipine in a patient with eclampsia: color flow Doppler demonstration of retinal artery relaxation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Intrapartum treatment of preeclamptic hypertension by ketanserin

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The effect of serotonergic blockade in postpartum preeclamptic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Intrapartum treatment of preeclamptic hypertension by ketanserin--a serotonin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Ketanserin for the treatment of preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The hemodynamic effects of intubation during nitroglycerin infusion in severe preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The use of nitroglycerin in preventing the hypertensive response to tracheal intubation in severe preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Preeclampsia: an endothelial cell disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Treatment of pregnancy hypertension with prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

The hypertensive disorders of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

Pregnancy and ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2800%2900368-7

7 January 2021

10.1016/S0301-2115(00)00368-7

Identifiers

DOI

1 reference

31 July 2017

1 reference